Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 7
Submit an article Journal homepage
99
Views
7
CrossRef citations to date
0
Altmetric
Review

Multivessel coronary artery disease: quantifying how recent trials should influence clinical practice

Ruben LJ Osnabrugge Department of Cardio-Thoracic Surgery, Erasmus University Medical Center, PO Box 2040, Rotterdam, The Netherlands
,
Stuart J Head Department of Cardio-Thoracic Surgery, Erasmus University Medical Center, PO Box 2040, Rotterdam, The Netherlands
,
Ad JJC Bogers Department of Cardio-Thoracic Surgery, Erasmus University Medical Center, PO Box 2040, Rotterdam, The Netherlands
&
A Pieter Kappetein Department of Cardio-Thoracic Surgery, Erasmus University Medical Center, PO Box 2040, Rotterdam, The Netherlands. [email protected]
Pages 903-918 | Published online: 10 Jan 2014

References

  • Garrett HE, Dennis EW, DeBakey ME. Aortocoronary bypass with saphenous vein graft. Seven-year follow-up. JAMA 223(7), 792–794 (1973).
  • Gersh BJ, Kronmal RA, Frye RL et al. Coronary arteriography and coronary artery bypass surgery: morbidity and mortality in patients ages 65 years or older. A report from the Coronary Artery Surgery Study. Circulation 67(3), 483–491 (1983).
  • Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301(2), 61–68 (1979).
  • Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001–2008. JAMA 305(17), 1769–1776 (2011).
  • Kappetein AP, Dawkins KD, Mohr FW et al. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. Eur. J. Cardiothorac. Surg. 29(4), 486–491 (2006).
  • Ong AT, Serruys PW, Mohr FW et al. The SYNergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) study: design, rationale, and run-in phase. Am. Heart J. 151(6), 1194–1204 (2006).
  • Farkouh ME, Dangas G, Leon MB et al. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am. Heart J. 155(2), 215–223 (2008).
  • Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 68(5), 939–950 (1983).
  • Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N. Engl. J. Med. 311(21), 1333–1339 (1984).
  • Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N. Engl. J. Med. 319(6), 332–337 (1988).
  • Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344(8922), 563–570 (1994).
  • Fihn SD, Gardin JM, Abrams J et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 60(24), e44–e164 (2012).
  • Kolh P, Wijns W, Danchin N et al. Guidelines on myocardial revascularization. Eur. J. Cardiothorac. Surg. 38(Suppl.), S1–S52 (2010).
  • Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 350(9076), 461–468 (1997).
  • Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 111(22), 2906–2912 (2005).
  • Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N. Engl. J. Med. 326(1), 10–16 (1992).
  • Hueb W, Lopes NH, Gersh BJ et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115(9), 1082–1089 (2007).
  • Boden WE, O’Rourke RA, Teo KK et al.; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356(15), 1503–1516 (2007).
  • De Bruyne B, Pijls NH, Kalesan B et al.; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N. Engl. J. Med. 367(11), 991–1001 (2012).
  • Weintraub WS, Spertus JA, Kolm P et al.; COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N. Engl. J. Med. 359(7), 677–687 (2008).
  • Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch. Intern. Med. 172(4), 312–319 (2012).
  • Shaw LJ, Berman DS, Maron DJ et al.; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117(10), 1283–1291 (2008).
  • Boden WE. Which is more enduring – FAME or COURAGE? N. Engl. J. Med. 367(11), 1059–1061 (2012).
  • Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108(14), 1664–1672 (2003).
  • Hannan EL, Samadashvili Z, Cozzens K et al. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation 125(15), 1870–1879 (2012).
  • Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 305(18), 1882–1889 (2011).
  • Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation 121(12), 1455–1458 (2010).
  • Ho PM, Magid DJ, Shetterly SM et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart J. 155(4), 772–779 (2008).
  • Hlatky MA, Solomon MD, Shilane D, Leong TK, Brindis R, Go AS. Use of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary intervention. J. Am. Coll. Cardiol. 61(3), 295–301 (2013).
  • Boden WE, Franklin BA, Wenger NK. Physical activity and structured exercise for patients with stable ischemic heart disease. JAMA 309(2), 143–144 (2013).
  • Bravata DM, Gienger AL, McDonald KM et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann. Intern. Med. 147(10), 703–716 (2007).
  • Daemen J, Boersma E, Flather M et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 118(11), 1146–1154 (2008).
  • Hlatky MA, Boothroyd DB, Bravata DM et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373(9670), 1190–1197 (2009).
  • Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 341(8845), 573–580 (1993).
  • Rodriguez A, Boullon F, Perez-Baliño N, Paviotti C, Liprandi MI, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J. Am. Coll. Cardiol. 22(4), 1060–1067 (1993).
  • Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N. Engl. J. Med. 331(16), 1037–1043 (1994).
  • King SB 3rd, Lembo NJ, Weintraub WS et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N. Engl. J. Med. 331(16), 1044–1050 (1994).
  • First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. Lancet 346(8984), 1179–1184 (1995).
  • Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N. Engl. J. Med. 335(4), 217–225 (1996).
  • Carrié D, Elbaz M, Puel J et al. Five-year outcome after coronary angioplasty versus bypass surgery in multivessel coronary artery disease: results from the French Monocentric Study. Circulation 96(Suppl. 9), II–I1 (1997).
  • Morrison DA, Sethi G, Sacks J et al.; Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J. Am. Coll. Cardiol. 38(1), 143–149 (2001).
  • Rodriguez A, Bernardi V, Navia J et al. Argentine randomized study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J. Am. Coll. Cardiol. 37(1), 51–58 (2001).
  • So SI. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 360(9338), 965–970 (2002).
  • Eefting F, Nathoe H, van Dijk D et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation 108(23), 2870–2876 (2003).
  • Hueb W, Soares PR, Gersh BJ et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J. Am. Coll. Cardiol. 43(10), 1743–1751 (2004).
  • Pohl T, Giehrl W, Reichart B et al. Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheter. Cardiovasc. Interv. 62(3), 323–330 (2004).
  • Serruys PW, Ong AT, van Herwerden LA et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J. Am. Coll. Cardiol. 46(4), 575–581 (2005).
  • Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 379(9824), 1393–1402 (2012).
  • Benedetto U, Melina G, Angeloni E et al. Coronary artery bypass grafting versus drug-eluting stents in multivessel coronary disease. A meta-analysis on 24,268 patients. Eur. J. Cardiothorac. Surg. 36(4), 611–615 (2009).
  • Serruys PW, Morice MC, Kappetein AP et al.; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360(10), 961–972 (2009).
  • Mohr FW, Kappetein AP et al. Final five-year follow-up of the SYNTAX Trial: optimal revascularisation strategy in patients with three-vessel disease and/or left main disease. Lancet 381(9867), 629–638 (2013).
  • Kappetein AP, Feldman TE, Mack MJ et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur. Heart J. 32(17), 2125–2134 (2011).
  • Taggart DP. Lessons learned from the SYNTAX trial for multivessel and left main stem coronary artery disease. Curr. Opin. Cardiol. 26(6), 502–507 (2011).
  • Weintraub WS, Grau-Sepulveda MV, Weiss JM et al. Comparative effectiveness of revascularization strategies. N. Engl. J. Med. 366(16), 1467–1476 (2012).
  • Hannan EL, Wu C, Walford G et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N. Engl. J. Med. 358(4), 331–341 (2008).
  • Jeon C, Candia SC, Wang JC et al. Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: a model for protection from acute myocardial infarction. Am. Heart J. 160(1), 195–201 (2010).
  • Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J. Am. Coll. Cardiol. 41(7), 1071–1077 (2003).
  • Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur. Heart J. 32(22), 2748–2757 (2011).
  • Groot MW, Head SJ, Bogers AJ, Kappetein AP. Coronary revascularization in diabetic patients. A focus on the 3-year SYNTAX trial outcomes. Herz 37(3), 281–286 (2012).
  • Schramm TK, Gislason GH, Køber L et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117(15), 1945–1954 (2008).
  • A randomized trial of therapies for Type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360(24), 2503–2515 (2009).
  • Maron DJ, Boden WE, Spertus JA et al.; COURAGE Trial Research Group. Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J. Am. Coll. Cardiol. 58(2), 131–137 (2011).
  • Henderson RA, Pocock SJ, Clayton TC et al.; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J. Am. Coll. Cardiol. 42(7), 1161–1170 (2003).
  • King SB 3rd, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J. Am. Coll. Cardiol. 35(5), 1116–1121 (2000).
  • Kurbaan AS, Bowker TJ, Ilsley CD, Sigwart U, Rickards AF; CABRI Investigators (Coronary Angioplasty versus Bypass Revascularization Investigation). Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am. J. Cardiol. 87(8), 947–950; A3 (2001).
  • Kappetein AP, Head SJ, Morice MC et al.; SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur. J. Cardiothorac. Surg. 43(5), 1006–1013 (2013).
  • Kapur A, Hall RJ, Malik IS et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J. Am. Coll. Cardiol. 55(5), 432–440 (2010).
  • Farkouh ME, Domanski M, Sleeper LA et al.; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N. Engl. J. Med. 367(25), 2375–2384 (2012).
  • Hlatky MA. Compelling evidence for coronary-bypass surgery in patients with diabetes. N. Engl. J. Med. 367(25), 2437–2438 (2012).
  • Guyatt GH, Haynes RB, Jaeschke RZ et al. Users’ Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users’ Guides to patient care. Evidence-Based Medicine Working Group. JAMA 284(10), 1290–1296 (2000).
  • Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297(11), 1233–1240 (2007).
  • Taggart DP. Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know. Ann. Thorac. Surg. 82(6), 1966–1975 (2006).
  • Bourassa MG, Roubin GS, Detre KM et al. Bypass Angioplasty Revascularization Investigation: patient screening, selection, and recruitment. Am. J. Cardiol. 75(9), 3C–8C (1995).
  • Head SJ, Holmes DR Jr, Mack MJ et al.; SYNTAX Investigators. Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. JACC. Cardiovasc. Interv. 5(6), 618–625 (2012).
  • Osnabrugge RL, Head SJ, Bogers AJ, Kappetein AP. Appropriate coronary artery bypass grafting use in the percutaneous coronary intervention era: are we finally making progress? Semin. Thorac. Cardiovasc. Surg. 24(4), 241–243 (2012).
  • Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J. Am. Coll. Cardiol. 59(9), 857–881 (2012).
  • Hannan EL, Cozzens K, Samadashvili Z et al. Appropriateness of coronary revascularization for patients without acute coronary syndromes. J. Am. Coll. Cardiol. 59(21), 1870–1876 (2012).
  • Ko DT, Guo H, Wijeysundera HC et al.; Cardiac Care Network (CCN) of Ontario Variations in Revascularization Practice in Ontario (VRPO) Working Group. Assessing the association of appropriateness of coronary revascularization and clinical outcomes for patients with stable coronary artery disease. J. Am. Coll. Cardiol. 60(19), 1876–1884 (2012).
  • Head SJ, Kaul S, Mack M et al. The rationale for Heart Team decision-making for patients with stable complex coronary artery disease. Eur. Heart J. (2013) (In Press).
  • Chapman GB, Elstein AS. Valuing the future: temporal discounting of health and money. Med. Decis. Making 15(4), 373–386 (1995).
  • Beller GA. Quality measures and practice guidelines: are they being embraced by cardiologists? J. Nucl. Cardiol. 19(4), 641–642 (2012).
  • Chan PS, Patel MR, Klein LW et al. Appropriateness of percutaneous coronary intervention. JAMA 306(1), 53–61 (2011).
  • Patel MR. Appropriate use criteria to reduce underuse and overuse: striking the right balance. J. Am. Coll. Cardiol. 60(19), 1885–1887 (2012).
  • Osnabrugge RL, Head SJ, Bogers AJ, Kappetein AP. Towards excellence in revascularization for left main coronary artery disease. Curr. Opin. Cardiol. 27(6), 604–610 (2012).
  • Farooq V, Brugaletta S, Serruys PW. Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention. Heart 97(23), 1902–1913 (2011).
  • Sianos G, Morel MA, Kappetein AP et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1(2), 219–227 (2005).
  • Shahian DM, O’Brien SM, Filardo G et al.; Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1 – coronary artery bypass grafting surgery. Ann. Thorac. Surg. 88(Suppl. 1), S2–S22 (2009).
  • Ranucci M, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation 119(24), 3053–3061 (2009).
  • Nashef SA, Roques F, Sharples LD et al. EuroSCORE II. Eur. J. Cardiothorac. Surg. 41(4), 734–745 (2012).
  • Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European System for Cardiac Operative Risk Evaluation (EuroSCORE). Eur. J. Cardiothorac. Surg. 16(1), 9–13 (1999).
  • Garg S, Sarno G, Garcia-Garcia HM et al.; ARTS-II Investigators. A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX Score. Circ. Cardiovasc. Interv. 3(4), 317–326 (2010).
  • Farooq V, Vergouwe Y, Räber L et al. Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur. Heart J. 33(24), 3098–3104 (2012).
  • Chen SL, Chen JP, Mintz G et al. Comparison between the NERS (New Risk Stratification) score and the SYNTAX (SYNergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery) score in outcome prediction for unprotected left main stenting. JACC Cardiovasc. Interv. 3(6), 632–641 (2010).
  • Capodanno D, Miano M, Cincotta G et al. EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention. Am. Heart J. 159(1), 103–109 (2010).
  • Capodanno D, Capranzano P, Di Salvo ME et al. Usefulness of SYNTAX score to select patients with left main coronary artery disease to be treated with coronary artery bypass graft. JACC Cardiovasc. Interv. 2(8), 731–738 (2009).
  • Peterson ED, Dai D, DeLong ER et al.; NCDR Registry Participants. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J. Am. Coll. Cardiol. 55(18), 1923–1932 (2010).
  • Siregar S, Groenwold RH, de Heer F, Bots ML, van der Graaf Y, van Herwerden LA. Performance of the original EuroSCORE. Eur. J. Cardiothorac. Surg. 41(4), 746–754 (2012).
  • Barili F, Pacini D, Capo A et al. Does EuroSCORE II perform better than its original versions? A multicentre validation study. Eur. Heart J. 34(1), 22–29 (2013).
  • Romagnoli E, Burzotta F, Trani C et al. EuroSCORE as predictor of in-hospital mortality after percutaneous coronary intervention. Heart 95(1), 43–48 (2009).
  • Head SJ, Farooq V, Serruys PW, Kappetein AP. The SYNTAX score and its clinical implications. Heart doi:heartjnl-2012-302482 (2013) (Epub ahead of print).
  • de Mulder M, Gitt A, van Domburg R et al. EuroHeart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention. Eur. Heart J. 32(11), 1398–1408 (2011).
  • Serruys PW, Farooq V, Vranckx P et al. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. JACC Cardiovasc. Interv. 5(6), 606–617 (2012).
  • Farooq V, van Klaveren D, Steyerberg EW et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 381(9867), 639–650 (2013).
  • Head SJ, Kaul SJ, Mack MJ et al. The rationale for Heart Team decision-making for patients with stable complex coronary artery disease. Eur. Heart J. doi:10.1093/eurheartj/eht059 (2013) (Epub ahead of print).
  • Haynes AB, Weiser TG, Berry WR et al.; Safe Surgery Saves Lives Study Group. A surgical safety checklist to reduce morbidity and mortality in a global population. N. Engl. J. Med. 360(5), 491–499 (2009).
  • Arriaga AF, Bader AM, Wong JM et al. Simulation-based trial of surgical-crisis checklists. N. Engl. J. Med. 368(3), 246–253 (2013).
  • Go AS, Mozaffarian D, Roger VL et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 127(1), e6–e245 (2013).
  • Roehr B. Increase in US healthcare costs should be no more than growth rate of economy, report says. BMJ, 346, f233 (2013).
  • Cohen DJ, Lavelle TA, Van Hout B et al. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. Catheter. Cardiovasc. Interv. 79(2), 198–209 (2012).
  • Favarato D, Hueb W, Gersh BJ et al.; First year follow-up of MASS II study. Relative cost comparison of treatments for coronary artery disease: the first year follow-up of MASS II study. Circulation 108(Suppl. 1), II21–II23 (2003).
  • Henderson RA, Pocock SJ, Sharp SJ et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet 352(9138), 1419–1425 (1998).
  • Hlatky MA, Boothroyd DB, Melsop KA et al. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation 110(14), 1960–1966 (2004).
  • Hlatky MA, Rogers WJ, Johnstone I et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N. Engl. J. Med. 336(2), 92–99 (1997).
  • Legrand VM, Serruys PW, Unger F et al.; Arterial Revascularization Therapy Study (ARTS) Investigators. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 109(9), 1114–1120 (2004).
  • Magnuson EA, Farkouh ME, Fuster V et al.; FREEDOM Trial Investigators. Cost–effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation 127(7), 820–831 (2013).
  • Rodriguez A, Mele E, Peyregne E et al. Three-year follow-up of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease (ERACI). J. Am. Coll. Cardiol. 27(5), 1178–1184 (1996).
  • Sculpher MJ, Seed P, Henderson RA et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 344(8927), 927–930 (1994).
  • Serruys PW, Unger F, Sousa JE et al.; Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N. Engl. J. Med. 344(15), 1117–1124 (2001).
  • Stroupe KT, Morrison DA, Hlatky MA et al.; Investigators of Veterans Affairs Cooperative Studies Program #385 (AWESOME: Angina With Extremely Serious Operative Mortality Evaluation). Cost–effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation 114(12), 1251–1257 (2006).
  • Vieira RD, Hueb W, Hlatky M et al. Cost–effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial. Circulation 126(11 Suppl. 1), S145–S150 (2012).
  • Weintraub WS, Becker ER, Mauldin PD, Culler S, Kosinski AS, King SB 3rd. Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST). Am. J. Cardiol. 86(7), 747–752 (2000).
  • Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King SB 3rd. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 92(10), 2831–2840 (1995).
  • Mack MJ. Health economic outcomes of the SYNTAX trial. Catheter. Cardiovasc. Interv. 79(2), 210 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.